Canada’s Competition Bureau has addressed growing concerns across the globe over the pharmaceutical industry’s use of patents to block competition, and its Commissioner, John Pecman, outlined how Canada will tackle the issue.
Pecman spoke at a conference this week on the topic of Global Antitrust Challenges for the Pharmaceutical Industry, focusing on the issue of patent litigation settlement agreements that delay the entry of cheaper, generic drugs. The agreements are known as pay-for-delay deals.
Pecman announced a white paper, “Patent Litigation Settlement Agreements: A Canadian Perspective” to address the role of the Bureau in the matter.
The Commissioner said the Bureau would review potentially anticompetitive pay-for-delay deals with a strong emphasis on blocking any abuse of dominance.
Full content: EIN News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI